MaxCyte Reports Q4 2025 Earnings: Revenue Down 15%, Core Revenue Diversification Improves

MaxCyte (MXCT) reported Q4 2025 revenue of $7.3 million, a 16% decline from the prior year. Total 2025 revenue was $33 million, down 15% from 2024. The company expects $4 million in core revenue headwinds in 2026 due to SPL program discontinuations and a major customer's reorganization. Revenue guidance for 2026 is between $30 million and $32 million, with a cash position of at least $136 million at the end of 2026.